• General Aspects of Neuroscience Drug Discovery and Development
• 55 min
  1. Is there a role for academia in drug discovery

  • Dr. Adrian J. Ivinson
• 33 min
  2. Receptor-channel research at the interface between academia and pharma

  • Prof. Mihaly Hajos
• Seizure Disorders
• 35 min
  3. Discovery of Levetiracetam (Keppra(R)): The first SV2A ligand for the treatment of epilepsy

  • Dr. Henrik Klitgaard
• 47 min
  4. Anti-seizure drugs: discovery and development

  • Dr. Roger Porter
• Alzheimer's Disease
• 54 min
  5. Abeta toxicity 1

  • Prof. Colin L. Masters
• 28 min
  6. Abeta toxicity 2

  • Prof. Colin L. Masters
• 68 min
  7. Targeting Aß oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer’s disease

  • Prof. William L. Klein
• 19 min
  8. Pathogenic mechanisms and therapeutic approaches for the tauopathies

  • Prof. Karen Duff
• 31 min
  9. Update on fluid biomarkers for neurodegenerative diseases

  • Prof. Henrik Zetterberg
• Parkinson's Disease
• 51 min
  10. Disease-modifying therapies for Parkinson's disease

  • Dr. Todd Sherer
• Schizophrenia
• 20 min
  11. Discovery of schizophrenia drug targets from DISC1 mechanisms

  • Prof. Atsushi Kamiya
• 33 min
  12. Animal models for schizophrenia

  • Dr. Mikhail Pletnikov
• Archived Lectures *These may not cover the latest advances in the field
• 23 min
  13. Biomarkers for Alzheimer's disease

  • Prof. Henrik Zetterberg

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. The Australian study of ageing (AIBL)
3. Methodology - key outcomes
4. AIBL design
5. Demographics
6. PIB and other ligands
7. Abeta imaging
8. Amyloid imaging
9. 11C-PIB in the differential diagnosis of AD
10. The progression of AD
11. Familial AD
12. Selective vulnerability
13. Abeta burden quantification
14. PiB- frequency distribution
15. Abeta and memory
16. Abeta and memory (HC)
17. Abeta and memory (MCI)
18. Prediction of conversion from HC to MCI/AD
19. Prediction of conversion from MCI to AD
20. Impact of amyloid imaging in MCI patient
21. Longitudinal PiB PET follow-up (1)
22. Longitudinal PiB PET follow-up (2)
23. Longitudinal PiB PET 5-year follow-up
24. Hippocampal volume by clinical classification
25. Abeta burden and regional grey matter volume
26. Linear regression of PiB PET imaging
27. Baseline plasma Abeta 42 & 42/40 (AIBL cohort)
28. Plasma Abeta 42 levels (PiB-PET AIBL subset)
29. Correlating Abeta in blood, cognition & PiB SUVR
30. Mean of ApoE levels within clinical categories
31. Plasma ApoE (total) levels: AIBL study
32. Plasma ApoE4 levels vs. PiB-PET: AIBL study
33. Biomarker discovery
34. Preclinical Alzheimer's disease
35. Abeta deposition
36. Abnormal protein/RNA conformations
37. The AIBL study team
38. Neurodegeneration research group
39. Collaborators

Topics Covered

• The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing
• Methodology: key outcomes
• Abeta and amyloid imaging
• The progression of AD
• Abeta and memory
• Prediction of conversion from HC to MCI/AD
• Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials
• Longitudinal PiB PET follow-up
• Plasma Abeta 42 levels in the PiB-PET AIBL subset
• Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR
• Plasma ApoE (total) levels: the AIBL study
• Biomarker discovery
• Abeta deposition

Links

Series:

• Alzheimer's Disease
• Drug Discovery and Development in the Neurosciences

Categories:

• Clinical Practice
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on October 27, 2011

Financial Disclosures

• Prof. Colin L. Masters has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.